Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The goal of the present study is to assess, through a randomized phase II trial, the efficacy and safety of Lenalidomide with or without Epoetin beta in transfusion-dependent, ESA-resistant, IPSS low and intermediate-1 risk MDS patients without chromosome 5 abnormality.

Patients will receive either Lenalidomide alone or Lenalidomide and Epoetin beta for 4 months. Responders will be eligible for maintenance treatment with cycles identical to the first cycles, until relapse occurs or until unacceptable toxicity.

Condition or disease	Intervention/treatment	Phase
Myelodysplastic Syndromes	Drug: Lenalidomide; Drug: Epoetin beta	Phase 2

Detailed Description:

This is a multi-center, open-label, randomized, Phase II study.

Patients will be treated either with arm A or B

• Arm A: Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses.
• Arm B: Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses combined with weekly subcutaneous injections of Epoetin beta (60,000 Units/w).

Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.

Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.

in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.

The patients will be followed every 3 months for 12 months

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	132 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Phase II Study Evaluating the Efficacy/Safety of Lenalidomide With or Without Epoetin Beta in Transfusion-dependent ESA-resistant Patients With IPSS Low- and Intermediate-1 Risk Myelodysplastic Syndromes Without Chromosome 5 Abnormality.
Study Start Date :	July 2010
Actual Primary Completion Date :	November 2012
Actual Study Completion Date :	June 2016

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Arm A; Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses. Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria. Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician. The patients will be followed every 3 months for 12 months	Drug: Lenalidomide; Lenalidomide:10 mg per day during 21 days; Other Name: Revlimid
Experimental: Arm B; Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses combined with weekly subcutaneous injections of Epoetin beta (60,000 Units/w). Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria. Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician. The patients will be followed every 3 months for 12 months	Drug: Epoetin beta; Epoetin beta: 60,000 Units/week.; Other Name: NEORECORMON

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Comparing the efficacy of Lenalidomide alone to Lenalidomide with Epoetin beta in transfusion-dependent ESA-resistant [ Time Frame: After 4 months of treatment ]

   Primary outcome is a complete or partial response defined by the IWG 2006 criteria observed after 4 months of treatment. Comparison in the rate of response between the two groups will be performed with Chi-square test or if necessary Fisher exact test.

   Same analyzes will be performed with the IWG 2000 response definition .

Secondary Outcome Measures :

1. will be to assess the safety of Lenalidomide and of its combination with Epoetin beta [ Time Frame: After 2 months of treatment ]
   • Safety of Lenalidomide and of its combination with Epoetin beta: adverse events (type, frequency, severity) and relationship of adverse events to study drug
   • % of major HI-E and minor HI-E after 4 courses according to IWG 2000 criteria
   • Erythroid response duration
   • Time to response
   • Time to progression according to IPSS
   • RBC transfusion independence
   • Prognostic factors of response
   • Survival
   • Quality of life

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

MDS defined as

• Low or int-1 IPSS score
• Documented absence of chromosome 5 abnormality (del(5q) or -5 karyotype)
• De novo MDS, excluding therapy-related MDS AND
• Transfusion dependance (requirement of at least 4 units of RBC transfusions every 8 weeks )
• Resistance or loss of response to a previous treatment with Epoetin alpha/beta (at least 60,000 Units/w) or Darbepoetin (at least 250 µg/w), for at least 12 weeks
• Ineligibility for allogeneic stem cell transplantation or intensive chemotherapy during the next 12 months
• ECOG performance status ≤ 2
• Age ≥ 18 years
• Life expectancy ≥ 3 months
• Adequate liver function (transaminases serum levels ≤ 3N)
• Adequate renal function (calculate creatinine clearance > 50 ml/min)
• Female subjects of chilbearing potential* must :

Agree to use effective contraception without interruption throughout the study and for at least 4 weeks after the end of treatment

• Men must: Agree to not conceive during the treatment and to use effective contraception during the treatment period (including periods of dose reduction or temporary suspension) and during one week after end of treatment if their partner is of childbearing potential.

Exclusion Criteria:

• Active serious infection not controlled by oral or intravenous antibiotics
• Platelets less than 50 G/L
• Prior history of deep vein thrombosis or pulmonary embolism
• Previous treatment by Thalidomide
• Treatment with any investigational antileukemic agent or chemotherapy at least 6 weeks prior to study entry and lack of full recovery from side effects due to prior therapy independent of when that therapy were given
• Rapidely progressive disease with copromised organ function judged to be life-threatening by the Investigator
• Pregnant or lactating female
• Known human immunodeficiency virus (HIV) infection
• Known active hepatitis B and/or C virus infection
• Hypersensitivity or intolerance to Lenalidomide or any of the excipients
• Hypersensitivity to Epoetin beta or any of the excipients
• Uncontrolled arterial hypertension
• Any history of malignancy (other than myelodysplastic syndrome) unless the patient has remained disease free for more than 5 years

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

  Show 48 Study Locations

Sponsors and Collaborators

Groupe Francophone des Myelodysplasies

Celgene

Roche Pharma AG

Investigators

Principal Investigator:	Andréa TOMA, MD	Groupe Francophone des Myelodysplasies
Study Director:	François Dreyfus, MD	Groupe Francophone des Myelodysplasies

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Chesnais V, Renneville A, Toma A, Lambert J, Passet M, Dumont F, Chevret S, Lejeune J, Raimbault A, Stamatoullas A, Rose C, Beyne-Rauzy O, Delaunay J, Solary E, Fenaux P, Dreyfus F, Preudhomme C, Kosmider O, Fontenay M; Groupe Francophone des Myélodysplasies. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood. 2016 Feb 11;127(6):749-60. doi: 10.1182/blood-2015-04-640128. Epub 2015 Dec 1.

Responsible Party:	Groupe Francophone des Myelodysplasies
ClinicalTrials.gov Identifier:	NCT01718379 History of Changes
Other Study ID Numbers:	GFM-Len-Epo-08
First Posted:	October 31, 2012
Last Update Posted:	November 8, 2016
Last Verified:	November 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Keywords provided by Groupe Francophone des Myelodysplasies:

Myelodysplasia

Additional relevant MeSH terms:

Syndrome; Myelodysplastic Syndromes; Preleukemia; Disease; Pathologic Processes; Bone Marrow Diseases; Hematologic Diseases; Precancerous Conditions; Neoplasms; Lenalidomide; Thalidomide; Epoetin Alfa	Immunologic Factors; Physiological Effects of Drugs; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Antineoplastic Agents; Immunosuppressive Agents; Leprostatic Agents; Anti-Bacterial Agents; Anti-Infective Agents; Hematinics